Introduction
============

Lung cancer has always been the most dominant cancer subtype. According to the latest statistics, the incidence and mortality of lung cancer have consistently occupied the top spot either in the country or worldwide and far outpaces other types of malignant tumors ([@b1-mmr-16-06-8781]). Because there is no pertinent early diagnosis or optimal tissue-based molecular diagnostic procedure, lung cancer is usually in the advanced stages when diagnosed ([@b2-mmr-16-06-8781]). Additionally, non-small cell lung cancer (NSCLC) accounts for 80% of the total number of lung cancer cases, including adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC) ([@b3-mmr-16-06-8781]). Despite great efforts in elucidating the occurrence, development and prognosis of NSCLC in recent years, researchers still have not illuminated the potential tumorigenesis mechanism of NSCLC to date. As a consequence, studies are required to further develop a novel molecular-target diagnosis and therapy targeting NSCLC.

MicroRNAs (miRNAs), which are 20--25 nt in length, are a type of endogenous non-coding small RNA that regulates gene expression at either the messenger RNA (mRNA) or protein level during the post-transcription period ([@b4-mmr-16-06-8781],[@b5-mmr-16-06-8781]). miRNA can either inhibit the translation of mRNA or directly induce mRNA degradation by binding to the 3′ untranslated regions (3′UTRs) of mRNA ([@b6-mmr-16-06-8781]); these processes can promote or restrain the proliferation, transformation, differentiation, apoptosis and necrosis of cells ([@b6-mmr-16-06-8781]--[@b8-mmr-16-06-8781]). Evidence has shown that abnormal miRNA expression is relative to the tumorigenesis process of several types of cancer ([@b9-mmr-16-06-8781]), including NSCLC ([@b10-mmr-16-06-8781]). miRNA has become the valuable biomarkers in a variety of diseases ([@b11-mmr-16-06-8781]), especially cancer. miRNA can be used not only for NSCLC subtype analysis but also for monitoring the prognosis and recurrence of early stage NSCLC by identifying a specific sequence ([@b12-mmr-16-06-8781]--[@b16-mmr-16-06-8781]).

Previous studies had contrary conclusions that miR-146a acted to promote tumor growth in papillary thyroid carcinoma ([@b17-mmr-16-06-8781],[@b18-mmr-16-06-8781]) but also exerted tumor suppressor activities in malignancies located in the following organs: Breast ([@b19-mmr-16-06-8781]), prostate ([@b20-mmr-16-06-8781]--[@b22-mmr-16-06-8781]), pancreas ([@b23-mmr-16-06-8781]) and stomach ([@b24-mmr-16-06-8781]--[@b28-mmr-16-06-8781]). Regarding NSCLC, Wang *et al* reported that miR-146a had higher expression levels in NSCLC cells when compared with normal lung cells ([@b29-mmr-16-06-8781]). Meanwhile, our previous study ([@b30-mmr-16-06-8781]) concluded that miR-146a had low expression in NSCLC, but miR-146a mimic could inhibit cell proliferation and metastasis as well as induce apoptosis through the EGFR signaling pathway, which is in accordance with another published study ([@b31-mmr-16-06-8781]). Therefore, we intended to detect the clinical significance and function mechanism of miR-146a-5p (abbreviated as miR-146a) in NSCLC.

*In vivo* animal experiment models have become an important means of NSCLC studies. To date, the chick embryo chorioallantoic membrane (CAM) model has become an efficient experimental animal model for studying tumors because it is cheap, convenient, fast, simple and sensitive. Because of its natural immunodeficiency and abundant formation of new blood vessels and an arteriovenous network, the CAM model is suitable for researching the mechanisms of angiogenesis, invasion and metastasis ([@b32-mmr-16-06-8781]--[@b39-mmr-16-06-8781]).

In this study, we intended to investigate the effect and molecular mechanism by which miR-146a-5p affects NSCLC using a constructed miR-146a-5p-expressing H460 NSCLC cell line and transplanting the transduced cells into the CAM of chick embryos. By establishing a CAM xenograft tumor model, we simulated the tumorigenesis process of NSCLC and observed the resulting angiogenesis. In addition, the local invasive and necrosis conditions of tumor were measured using hematoxylin and eosin (H&E) staining. In addition, the prediction of target genes in silico also implicated the possible functional location and pathways of miR-146a-5p.

Materials and methods
=====================

### Ethics statement

This research project was conducted with the permission of the Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (Nanning, China).

### Cell cultivation and selection

NSCLC cell lines provided by Yangjie Experiment Center of Guangxi Medical University consisted of two different histological types: The human lung large cell cancer H460, and the lung adenocarcinoma cancer cell lines A549, PC9 and H1299. The NSCLC cell lines were cultured in either RPMI-1640 medium (H460, A549 and H1299) or Dulbecco\'s modified Eagle\'s medium (DMEM) PC9 at 37°C in a humidified environment containing 5% CO~2~. Detection of the miR-146a-5p expression levels in these lung cancer cell lines was performed to identify the cell line with the lowest expression levels of miR-146a-5p; this cell line (H460) was set aside for lentivirus transduction.

### RNA extraction and qRT-PCR

Operative steps for determining miR-146a-5p expression level were as follows. Total RNA was extracted using a total RNA extraction kit (no. 9767; Takara Biotechnology Co., Ltd., Dailan, China) according to the manufacturer\'s instructions. After determining the concentration and purity of the RNA by measuring the absorbance at 260 and 280 nm, cDNA was generated by applying Takara Mir-X™ miRNA First-Strand Synthesis. The reactions were prepared using the SYBR^®^ qRT-PCR User Manual. Primers were designed by using Online Prime 3.0, and then Invitrogen synthesized the primers.

### Lentivirus transduction and interference efficiency verification

hsa-miR-146a lentivirus (LV-hsa-miR-146a) and a negative control lentivirus (LV-no load, LVCON238) were both purchased from the Shanghai Jikai Gene Chemical Co., Ltd. (Shanghai, China) and stored at −80°C. The target sequence of miR-146a-5p (miRBase accession, MI0000477) was TGAGAACTGAATTCCATGGGTT, and the vector was GV369, which contained the component order Ubi-MCS-SV40-EGFP-IRES-puromycin. The sequence of the negative control was TTCTCCGAACGTGTCACGT. During the transduction process, the selected cell line H460 was divided into three groups: Blank control group (untreated non-transduced H460 lung cancer cell line), the experimental group (LV-hsa-miR-146a group) and the negative control group (LV-no load, LVCON238). Cell morphology and fluorescence intensity were monitored under the fluorescence microscope at 48 and 72 h after transduction, respectively. Finally, total RNA was extracted from the cell lines, and qRT-PCR was applied to quantify the relative miR-146a-5p expression.

### Chick embryo preparation

Fertilized chick embryos were purchased from Nanning Liangfeng Agriculture and Farming Company Limited. After it was sterilized in 75% alcohol, the chick embryo was placed in an incubation box (which was also sterilized by 75% alcohol) at 37.6--38°C with 70--80% humidity. The chick embryos were incubated until they were 8-day-old for experimental use.

### CAM tumor xenograft assay

i\) When the chick embryos were 7 days old, the contours of the embryoid body, gas chamber and large blood vessels attached to the chick chorioallantoic membrane on the egg shells were sketched under the exposure of an egg tester on sterile platform. ii) When the chick embryos were 8 day-old, they were removed and sterilized with 75% alcohol. A 2-mm diameter hole was drilled into the gas chamber side of every egg, and the embryo egg membrane was pricked with a fine needle. Next, an approximately 2×1 cm window was ground out on the egg shell near the embryoid body and large blood vessels to expose the white membrane. Afterwards, air was repeatedly suctioned through the previously drilled hole into the gas chamber to isolate the white membrane and chick chorioallantoic membrane. When the white membrane was removed to expose the vessels, a 5 mm silicon rubber ring was gently placed above the vessel rich area on the CAM. Finally, the small hole in the gas chamber was sealed up with sterile transparent materials. The above procedure was conducted on a sterile platform. iii) A cell suspension solution from each group was gently added to the silicon rubber ring, and the window was sealed using sterile transparent materials. After incubating for 24 h in the incubation box, the silicon rubber ring was removed, and the model system was then placed back into the incubation box to incubate for 120 h. Throughout this duration, the tumorigenesis condition was monitored and recorded every 24 h. iv) After 120 h, the chick embryo and sterile transparent materials were discarded, and the xenograft tumors were removed from the CAM. These tumors were photographed and measured to record their size. v) The vessel ratio and window\'s area were estimated by using Image-Pro Plus. vi) After embedding the tumors with paraffin, the samples were sliced and stained with HE-staining to observe the cellular morphology of tumor cell as well as the metastasis conditions.

### Identifying potential target genes in silico and bioinformatics analysis

The predicted and validated microRNA gene targets were obtained from miRWalk2.0 (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>). The twelve prediction databases were miRWalk, MicroT4, miRanda, mirbridge, miRDB, miRMap, miRNAMap, PicTar2, PITA, RNA22, RNAhybrid and TargetScan, and the three validated databases were miRTarBase, TarBase and miRecords. For predicting the target genes, those ones which were repeated in four or more databases were selected for the next step. The overlapping hits of the selected predicted genes and all the validated genes were entered into a gene-enrichment pathway analysis. Function analysis of the potential target genes from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations and Gene Ontology (GO) terms were provided by Database for Annotation, Visualization and Integrated Discovery 6.7 (DAVID 6.7, <https://david.ncifcrf.gov/>) ([@b40-mmr-16-06-8781]). The protein interaction analysis was showed by protein-protein interaction (PPI) Networks from Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, <http://www.string-db.org/>).

### Statistical analysis

Experimental data were analyzed using SPSS 20.0 (SPSS, Inc., Chicago, IL, USA) statistical software using methods such as the Independent Samples t-test, χ^2^ test and Spearman\'s correlation coefficient analysis, and α=0.05 was considered as the test threshold. When the two-sided P-values was \<0.05, the result was considered to indicate a statistically significant difference.

Results
=======

### The expression levels of miR-146a-5p in 4 cell lines

Total RNA extracted from the H460, PC9, 1299 and A549 cell lines were analyzed for concentration and purity. H460 cells presented the lowest expression level of miR-146a-5p than the other three cell lines; thus, H460 cells were selected to construct the CAM xenograft tumor model. The relative expression levels of miR-146a-5p in the 4 NSCLC cell lines were showed that H460 cells had the lowest miR-146a-5p expression among the cell lines tested.

### Lentivirus transduction outcomes

H460 cells were transduced with the optimal ratios for either LV-hsa-miR-146a or LV-no load ([Fig. 1](#f1-mmr-16-06-8781){ref-type="fig"}). The miR-146a-5p expression levels in H460 cells transduced with LV-hsa-miR-146a and LV-no load group were detected by qRT-PCR. The results showed that the H460 cells were successfully transduced with lentivirus and that the miR-146a-5p in LV-hsa-miR-146a groups presented obviously overexpression than the negative LV-no load group.

### CAM xenograft tumor model

The results of the xenograft tumor sizes from day 1 (24 h after inoculation, or day 8 of chick embryo growth) to day 5 (120 h after inoculation, or day 12 of chick embryo growth) were showed in [Figs. 2](#f2-mmr-16-06-8781){ref-type="fig"} and [3](#f3-mmr-16-06-8781){ref-type="fig"}. First, one-way analysis of variance (ANOVA) was performed, but the results were not statistically significant. Then, the independent sample t-test was performed by comparing the sizes with those of the blank control group. The size of the xenograft tumors in the experimental group (LV-hsa-miR-146a group, V=6.340±0.066 mm^3^) were obviously reduced compared with that in the blank control group (untreated H460 cell line, V=30.13±0.06 mm^3^) (t=613.489, P\<0.001), and the tumor size of the negative control group (V=30.09±0.07 mm^3^) exhibited no statistical significance when compared with the blank control group (untreated H460 cell line, V=30.13±0.06 mm^3^) (t=1.312, P=0.260).

### Angiogenesis of xenograft tumors

Based on the duration of the observed incubation period and final angiogenesis data ([Fig. 3](#f3-mmr-16-06-8781){ref-type="fig"}), the independent samples t-test was performed by comparing the results of the blank control group with the non-significant result of the one-way ANOVA. The appearance of the xenograft tumors on day 1 was an attached tumor on the CAM with a few capillary vessels thriving and surrounding the uneven surface of the xenograft tumor; by day 5, the angiogenesis conditions of the experimental group (LV-hsa-miR-146a group, 9.326±0.083) were largely reduced compared with those of the blank control group (untreated H460 cells, 16.94±0.11) (t=121.207, P\<0.001), while growth situation of vessel showed no significant difference between the negative control group (LV-no load group, 16.97±0.07) and the blank control group (untreated H460 cells, 16.94±0.11) (t=-0.612, P=0.573). Since tumor growth relies on the generation of blood vessels in the chick CAM model, the overexpression of miR-146a-5p in the experimental group inhibited the angiogenesis of the xenograft tumors and thus restrained tumor growth.

### H&E staining

Tumor tissue was removed, paraffin-embedded and subjected to HE-staining to observe the cell morphology ([Fig. 4](#f4-mmr-16-06-8781){ref-type="fig"}). Under a light microscope, all three groups could form tumors on the CAM and showed preservation of the primitive morphology of cancer, including obvious necrotic areas and inflammatory cell infiltration. However, the inflammatory condition of the experimental group (LV-hsa-miR-146a group) was relatively inconspicuous compared with that of the blank control group (untreated H460 cells).

### Potential target genes of miR-146a-5p based on bioinformatics analysis

Twelve in silico interaction tools to predict miRNA targets were used in this study. The databases were miRWalk, MicroT4, miRanda, miRBridge, miRDB, miRMap, miRNAMap, PicTar2, PITA, RNA22, RNAhybrid and TargetScan. In total, 14,278 target mRNAs were listed as predicted genes. Eight genes were predicted by ten databases in silico (FZD3, KLF7, STRBP, ZBTB2, IQGAP3, UPP2, JAZF1 and IER5L), which provides strong evidence that these genes are targets of miR-146a-5p. To improve the credibility of these target genes, we obtained 4,266 intersecting elements that were simultaneously predicted by at least four databases. Then, these elements were overlapped with all 589 validated target genes of miR-146a-5p using the databases miRTarBase, TarBase and miRecords to finally obtain 289 target genes ([Fig. 5](#f5-mmr-16-06-8781){ref-type="fig"}; [Table I](#tI-mmr-16-06-8781){ref-type="table"}).

The top 10 most significant KEGG pathway annotations were showed in [Table II](#tII-mmr-16-06-8781){ref-type="table"}. The most significant KEGG pathway was involved in cancer. Moreover, the top 10 GO terms of biological process (BP), cellular component (CC) and molecular function (MF) are listed in [Table III](#tIII-mmr-16-06-8781){ref-type="table"}, and the first terms of each analysis were cellular process, cell part and binding, respectively. The network of BP and CC are shown in [Figs. 6](#f6-mmr-16-06-8781){ref-type="fig"} and [7](#f7-mmr-16-06-8781){ref-type="fig"}. The most significant KEGG pathway (hsa05200, pathways in cancer) is shown in [Fig. 8](#f8-mmr-16-06-8781){ref-type="fig"}. The PPI network included 50 hub genes ([Fig. 9](#f9-mmr-16-06-8781){ref-type="fig"}). JUN, EGFR and RAC1 were the most relevant protein among the selected possible targets of miR-146a-5p.

Discussion
==========

Lung cancer has been consistently regarded as the most aggressive carcinoma worldwide and accounts for a large percentage of cancer-related deaths ([@b41-mmr-16-06-8781]). Although there is substantial amelioration in the application of chemical and molecular-targeted treatments, the prognosis of patients with lung carcinoma is still embarrassing ([@b42-mmr-16-06-8781]). Since the consensus behaviors of cancer cells-invasion and metastasis-are the major hurdles for the clinical treatment of NSCLC, more attention should be focused on the verification of small molecules that can suppress the invasion, metastasis and angiogenesis of NSCLC.

Recently, evidence demonstrated that miRNAs can be used as diagnostic and prognostic biomarkers of leukemia, lung cancer and colon cancer ([@b43-mmr-16-06-8781]). miRNAs may also be new therapeutic agents for antitumor therapies in humans ([@b44-mmr-16-06-8781]). One study found that miRNAs can regulate the signal transduction of the EGFR signaling pathway in a wide variety of tumor cells ([@b45-mmr-16-06-8781]), including lung cancer ([@b46-mmr-16-06-8781]). Identifying the molecules within the EGFR signaling pathway that are targeted by miRNAs may be a potential therapeutic approach for treating lung cancer. Previously, we found that low expression of miR-146a-5p in NSCLC cells inhibited cell proliferation and metastasis as well as induced apoptosis through the EGFR signaling pathway by using functional experiments ([@b30-mmr-16-06-8781]); these results were concomitant with another study conducted by Li *et al* ([@b31-mmr-16-06-8781]). In contrast to other studies on miR-146a-5p expression in NSCLC, this study verified the reliability of our previous experimental study *in vivo* to identify differences of biological growth properties and molecular variations among the CAM xenograft tumors comprising blank control, negative control or experimental cells.

Our previous study identified EGFR as a downstream regulatory target of miR-146a at both the mRNA and protein level ([@b30-mmr-16-06-8781]). The high expression of miR-146a inhibited the proliferation of NSCLC cells by downregulating the expression of EGFR. EGFR is a type of transmembrane glycoprotein receptor that functions as a tyrosine kinase (TK) ([@b47-mmr-16-06-8781]). Its conformational changes can cause receptor polymerization and induce the activation of the intracellular TK subregion to activate multiple signaling pathways, including the PLC-γ/PKCPI-3K/AKT, RAS-RAF-MEK-MAPK and STAT/NF-κB A pathways ([@b47-mmr-16-06-8781],[@b48-mmr-16-06-8781]). In different cells or at various differentiation stages, the EGFR configuration changes to activate different signaling pathways, and the cells react to the activation or inhibition of a series of downstream molecules in the signaling pathway ([@b49-mmr-16-06-8781]). This different signaling is in accordance with many other malignant tumors, such as gliomas and prostate cancer ([@b50-mmr-16-06-8781],[@b51-mmr-16-06-8781]). Moreover, EGFR mutations were found in cancerous and adjacent tissues of 10--40% of the lung cancer patients, among which 30% were Asian female non-smokers diagnosed with lung adenocarcinoma ([@b52-mmr-16-06-8781]). miR-146a-5p was showed to be an important regulatory factor in tumor formation mediated by EGFR, which provided a new theoretical basis for the treatment of patients with lung cancer. Monoclonal antibody D2-40, a specific biomarker of lymphatic epithelial cells, can show via immunohistochemical staining the profiles of small lymphatic vessels stretching from the alveolar space to the small blood vessels in the lung lobules. As a result, this technique can be applied to the identification of lymphatic vessel tumor emboli ([@b53-mmr-16-06-8781],[@b54-mmr-16-06-8781]).

In this study, we conducted a target mRNA prediction of miR-146a-5p using in silico methods. When combining the results of twelve prediction-based databases, we obtained theoretical target genes of miR-146a-5p. However, this artificial prediction could have limitations in this single computational algorithm, and this process still needs further experimental verification. Based on the predicted genes, KEGG pathways and GO enrichment analysis were conducted. Pathways involved in cancer and toll-like receptor signaling were the most two significant pathway groups of the target genes. In addition, the protein localization of the mRNAs was enriched in the cell membrane and functioned in cellular processes. For molecular function, the predicted genes were associated with binding. Then, we could predict that miR-146a-5p may participate in tumor-related intercellular protein or nucleic acid binding signaling behavior. We plan to conduct further experimental research on miR-146a-5p regarding the development of tumorigenesis. For the PPI network, network nodes represent proteins, and edges represent protein-protein associations. We obtained 50 hub genes to input into the PPI and found that JUN, EGFR and RAC1 were the most relevant protein names among the selected possible targets of miR-146a-5p.

miR-146a-5p was overexpressed in an NSCLC cell line and could inhibit the tumorigenesis and angiogenesis in a CAM xenograft tumor model. The in silico analysis revealed that its target genes are found in pathways related to cancer. miR-146a-5p is a potential tumor suppressor gene in NSCLC. The carcinogenic mechanism and its prognostic value in lung cancer needs further research.
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![The transduction outcomes of both H460 cells groups treated with lentivirus. The cells were transduced with (A) LV-hsa-miR-146a or (B) negative control. All cells were observed under a light microscope (×200).](MMR-16-06-8781-g00){#f1-mmr-16-06-8781}

![Tumor formation of (A) blank H460 lung cancer cells transduced with (B) either LV-no load or (C) LV-hsa-miR-146 in a chick chorioallantoic membrane.](MMR-16-06-8781-g01){#f2-mmr-16-06-8781}

![The chick chorioallantoic membrane (CAM) of tumor formation and angiogenesis. (A) Tumor formation of blank H460 cells and H460 cells transduced with either LV-no load (negative) or LV-hsa-miR-146 in CAM. (B) Overexpression of miR-146a-5p inhibited angiogenesis of tumors xenograft in CAM.](MMR-16-06-8781-g02){#f3-mmr-16-06-8781}

![Detection of the influence of miR-146a-5p overexpression on tumor formation using the chick chorioallantoic membrane (CAM) model \[hematoxylin and eosin staining (H&E)\]. (A) Blank H460 cells; (B) H460 cells transduced with negative control; and (C) H460 cells transduced with LV-hsa-miR-542 (from left to right in the order: 100, 200 and ×400 magnification).](MMR-16-06-8781-g03){#f4-mmr-16-06-8781}

![Flow diagram of the bioinformatic prediction of miR-146a-5p target genes.](MMR-16-06-8781-g04){#f5-mmr-16-06-8781}

![Network analysis with the prospective target genes of miR-146a-5p of BP. The intensity of the color indicates P-value size, node refers to pathways, and the node size is representative of the number of genes.](MMR-16-06-8781-g05){#f6-mmr-16-06-8781}

![Network analysis with the prospective target genes of miR-146a-5p of CC. The intensity of the color indicates P-value size, node refers to pathways, and the node size is representative of the number of genes.](MMR-16-06-8781-g06){#f7-mmr-16-06-8781}

![The top one Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of miR-146a-5p, hsa05200: Pathways in cancer.](MMR-16-06-8781-g07){#f8-mmr-16-06-8781}

![Hub gene protein-protein interaction (PPI) networks of the potential mRNAs targeted by miR-146a-5p.](MMR-16-06-8781-g08){#f9-mmr-16-06-8781}

###### 

Potential target genes of miR-146a-5p.

  ---------- ---------- ---------- ---------- ---------- ---------- --------- ----------
  IER5L      EIF4G2     SMAD4      STC1       CCDC6      MTA2       PHF20L1   LCOR
  CCDC117    THAP5      ELAVL1     IRAK1      NFIX       PRKCE      TCF20     BTG2
  SYNJ1      AP3S2      FNBP4      FBXO3      BRWD1      C12orf4    SRPRB     TRAK2
  KCTD15     ATG9A      CDC73      TMEM167A   ZNF367     HIPK1      ACTBL2    PTGS2
  RAC1       TIMELESS   RHOBTB3    BRK1       ITCH       ATP5G2     SLC26A2   EGFR
  ERBB4      NR6A1      MYO6       NF2        ROBO1      PPP1R11    TSPYL1    CASK
  NUMB       SERTAD2    MED13      WASF2      CARD8      MKRN2      FBXL3     C16orf72
  CARD10     FAM8A1     TMEM214    PLEKHG5    EPB41L4A   NSD1       DDHD1     TSPAN14
  VANGL1     NACC1      ARL8A      SESN3      SAMD9L     TMEM136    CD80      CD40LG
  CDKN3      EIF4EBP2   CFH        MR1        HSPA1A     IFIT3      PMAIP1    POU3F1
  PSMD3      RBL1       SFRP1      SLC2A3     STAT1      SF1        LSM4      METTL7A
  RUFY2      STARD7     RFX7       LIMD2      MOB1B      ZNF257     EDARADD   WDR36
  PTAR1      CCDC83     EFNA5      FANCF      IRF5       LBR        MID1      TLL1
  TRAF6      BCL7B      HYOU1      ARPP19     ZHX1       RAB18      AVL9      PDS5A
  TNRC6A     BABAM1     TULP4      GOPC       ATP13A3    EDEM3      TMPRSS5   SLC38A1
  STK40      RHPN2      TMEM67     SESTD1     EPSTI1     NACC2      HORMAD2   OLFML2A
  SKA2       TMPPE      BRCA1      BRCA2      CD86       GART       GPM6B     SMAD2
  MKLN1      MVD        PPP2R4     CCL5       SDCBP      SLC1A5     UMPS      CDS2
  CD84       AKAP8      CCR9       AAK1       ZNF629     ZNF117     ZDHHC13   GIMAP4
  PBLD       C1orf21    UTP15      USP48      ST6GAL2    RAB2B      ZNF493    ZNF260
  TRIM22     IGF2BP1    ERRFI1     MFSD6      RAB20      APMAP      GATAD2B   RAPH1
  PARD6B     BACH1      CALU       COPA       GNAI2      HOXB8      IREB2     NF1
  NFE2L1     RORA       SRPK1      RAD54L     SQSTM1     CPNE3      DEDD      ZBTB22
  SLK        TXNIP      SERBP1     RBM26      PAPD5      GRPEL1     ISG20L2   RASSF5
  TMEM101    ITPRIPL2   UBN2       ATXN1L     C16orf52   AKT2       LY75      POLR2E
  TLR4       TPD52      ZNF264     NUPL1      BTN2A2     COPS8      SNRNP27   CARHSP1
  STMN3      AEN        SIKE1      ATOH8      SYT12      VWCE       PLIN2     HLA-C
  LAMC2      STIM1      ULK1       MSC        RAPGEF5    MDFIC      PPHLN1    CYBRD1
  DGCR6L     SLFN11     PRR15      PA2G4      KLF9       CAPN2      JUN       TNPO1
  LNPEP      RPL11      CCL8       SOX4       WASL       LATS1      DDX21     ZBTB33
  G3BP1      SUPT16H    MDN1       STX12      IFIT5      CLIC4      KLHL20    NDC1
  KIAA1432   SHCBP1     KLHL15     CHMP4B     MTPN       DYNLL2     CPNE8     IFIT1
  LTB        FXR1       KIAA0040   ATP11B     PACS2      UHRF1      HM13      MRPL10
  ALG10B     ADD1       CCNA2      ELK4       MYLK       SERPINB9   NAPG      PAPOLA
  LMTK2      CBX6       SLC22A15   TXLNG      KLHL42     ACBD3      DBF4B     KBTBD6
  USP54      CNOT6L     ZNF410     P2RX5      RAG1       CXCL12     RER1      ETNK1
  TET3                                                                        
  ---------- ---------- ---------- ---------- ---------- ---------- --------- ----------

###### 

KEGG pathway enrichment analysis of miR-146a-5p.

  KEGG term                                                             Count (%)   P-value    Genes
  --------------------------------------------------------------------- ----------- ---------- ---------------------------------------------------------------------------------------
  hsa05200:Pathways in cancer                                           13 (4.6)    0.003466   EGFR, PTGS2, SMAD4, BRCA2, SMAD2, STAT1, CCDC6, RASSF5, JUN, RAC1, LAMC2, TRAF6, AKT2
  hsa04620:Toll-like receptor signaling pathway                         11 (3.9)    2.22E-06   IRAK1, CD86, IRF5, CD80, JUN, RAC1, TLR4, TRAF6, STAT1, CCL5, AKT2
  hsa04062:Chemokine signaling pathway                                    9 (3.2)   0.006907   CCR9, GNAI2, RAC1, CCL8, WASL, STAT1, CCL5, CXCL12, AKT2
  hsa04144:Endocytosis                                                    8 (2.8)   0.02061    EGFR, PARD6B, ERBB4, CHMP4B, HLA-C, HSPA1A, ITCH, TRAF6
  hsa05212:Pancreatic cancer                                              7 (2.5)   7.00E-04   EGFR, RAC1, SMAD4, BRCA2, SMAD2, STAT1, AKT2
  hsa04510:Focal adhesion                                                 7 (2.5)   0.082719   EGFR, JUN, RAC1, LAMC2, CAPN2, MYLK, AKT2
  hsa05416:Viral myocarditis                                              6 (2.1)   0.004174   EIF4G2, CD86, CD80, CD40LG, RAC1, HLA-C
  hsa04520:Adherens junction                                              6 (2.1)   0.005904   EGFR, WASF2, RAC1, SMAD4, SMAD2, WASL
  hsa05210:Colorectal cancer                                              6 (2.1)   0.008501   EGFR, JUN, RAC1, SMAD4, SMAD2, AKT2
  hsa04310:Wnt signaling pathway                                          6 (2.1)   0.077664   SFRP1, VANGL1, JUN, RAC1, SMAD4, SMAD2
  hsa04672:Intestinal immune network for IgA production                   5 (1.8)   0.006149   CCR9, CD86, CD80, CD40LG, CXCL12
  hsa04666:Fcγ R-mediated phagocytosis                                    5 (1.8)   0.055033   WASF2, RAC1, WASL, PRKCE, AKT2
  hsa05330:Allograft rejection                                            4 (1.4)   0.016657   CD86, CD80, CD40LG, HLA-C
  hsa05320:Autoimmune thyroid disease                                     4 (1.4)   0.041376   CD86, CD80, CD40LG, HLA-C
  hsa04621:NOD-like receptor signaling pathway                            4 (1.4)   0.066868   CARD8, CCL8, TRAF6, CCL5
  hsa05120:Epithelial cell signaling in Helicobacter pylori infection     4 (1.4)   0.083179   EGFR, JUN, RAC1, CCL5

###### 

Top 10 enrichment GO functional annotations for related targets of miR-146a-5p.

  GO ID                GO term                                    Count (%)     P-value       Gene symbol
  -------------------- ------------------------------------------ ------------- ------------- ---------------------------------------------------------------
  Biological process                                                                          
    GO:0009987         cellular process                           189 (67.0)    8.64E-04      GRPEL1, DBF4B, PTGS2, SLC22A15, CASK, TLR4, PMAIP1, RORA
    GO:0065007         biological regulation                      142 (50.4)    0.002032365   PTGS2, CASK, TLR4, PMAIP1, RORA, CXCL12, CBX6, EIF4EBP2
    GO:0050789         regulation of biological process           140 (49.6)    3.29E-04      PTGS2, CASK, TLR4, PMAIP1, RORA, CXCL12, CBX6, EIF4EBP2
    GO:0050794         regulation of cellular process             136 (48.2)    2.54E-04      PTGS2, CASK, TLR4, PMAIP1, RORA, CXCL12, CBX6, EIF4EBP2
    GO:0008152         metabolic process                          134 (47.5)    0.075818672   GRPEL1, PTGS2, CASK, RORA, CBX6, ACBD3, USP54, EIF4EBP2
    GO:0044238         primary metabolic process                  125 (44.3)    0.038487984   GRPEL1, PTGS2, CASK, RORA, CBX6, ACBD3, USP54, EIF4EBP2
    GO:0044237         cellular metabolic process                 121 (42.9)    0.032393623   GRPEL1, PTGS2, CASK, RORA, CBX6, USP54, EIF4EBP2, TRAK2
    GO:0043170         macromolecule metabolic process            111 (39.4)    0.005972279   GRPEL1, CASK, RORA, CBX6, USP54, EIF4EBP2, TRAK2, MDFIC, AAK1
    GO:0044260         cellular macromolecule metabolic process   105 (37.2)    0.002504917   GRPEL1, CASK, RORA, CBX6, USP54, EIF4EBP2, TRAK2, MDFIC
    GO:0019222         regulation of metabolic process            95 (33.7)     7.86E-08      BACH1, ZBTB33, DEDD, NR6A1, CASK, TLR4, RORA, LATS1
  Cellular component                                                                          
    GO:0044464         cell part                                  240 (85.1)    0.00492047    HM13, DBF4B, PTGS2, TMPPE, RORA, TPD52, ACBD3, TRAK2
    GO:0005623         cell                                       240 (85.1)    0.004971296   HM13, DBF4B, PTGS2, TMPPE, RORA, TPD52, ACBD3, TRAK2
    GO:0005622         intracellular                              202 (71.6)    4.68E-06      HM13, DBF4B, PTGS2, RORA, TPD52, ACBD3, TRAK2, RAPGEF5
    GO:0044424         intracellular part                         200 (70.9)    5.32E-07      HM13, DBF4B, PTGS2, RORA, TPD52, ACBD3, TRAK2, RAPGEF5
    GO:0043229         intracellular organelle                    163 (57.8)    0.001498556   GRPEL1, HM13, DBF4B, PTGS2, CHMP4B, CASK, PMAIP1, RORA
    GO:0043226         organelle                                  163 (57.8)    0.001618783   GRPEL1, HM13, DBF4B, PTGS2, CHMP4B, CASK, PMAIP1, RORA
    GO:0043231         intracellular membrane-bounded organelle   153 (54.3)    1.46E-04      GRPEL1, DBF4B, HM13, PTGS2, CHMP4B, CASK, PMAIP1, RORA
    GO:0043227         membrane-bounded organelle                 153 (54.3)    1.54E-04      GRPEL1, DBF4B, HM13, PTGS2, CHMP4B, CASK, PMAIP1, RORA
    GO:0005737         cytoplasm                                  136 (48.2)    0.003037975   GRPEL1, HM13, PTGS2, CHMP4B, CASK, TLR4, PMAIP1, TPD52
    GO:0005634         nucleus                                    117 (41.5)    3.70E-07      DBF4B, PTGS2, CASK, RORA, CBX6, TRAK2, MDFIC, LSM4
  Molecular function                                                                          
    GO:0005488         binding                                    223 (79.1)    8.09E-06      HM13, DBF4B, PTGS2, TMPPE, RORA, TPD52, ACBD3, USP54
    GO:0005515         protein binding                            169 (59.9)    1.90E-07      GRPEL1, HM13, PTGS2, CASK, TLR4, PMAIP1, RORA, TPD52
    GO:0003676         nucleic acid binding                         72 (25.5)   0.002025204   BACH1, ZBTB33, DBF4B, DEDD, SYNJ1, NR6A1, RORA, MKRN2
    GO:0003677         DNA binding                                  52 (18.4)   0.009158415   BACH1, ZBTB33, DEDD, NR6A1, RORA, SLK, ATOH8, LBR
    GO:0000166         nucleotide binding                           46 (16.3)   0.054477028   ACTBL2, GRPEL1, ERBB4, GNAI2, MVD, IGF2BP1, CASK, HSPA1A
    GO:0030528         transcription regulator activity             42 (14.9)   4.31E-04      BACH1, NR6A1, ZNF367, SOX4, NFIX, RORA, TCF20, ELK4
    GO:0017076         purine nucleotide binding                    42 (14.9)   0.027572564   ACTBL2, GRPEL1, ERBB4, GNAI2, MVD, CASK, HSPA1A, LATS1
    GO:0032555         purine ribonucleotide binding                41 (14.5)   0.022470925   ACTBL2, ERBB4, GNAI2, MVD, CASK, HSPA1A, LATS1, STK40
    GO:0032553         ribonucleotide binding                       41 (14.5)   0.022470925   ACTBL2, ERBB4, GNAI2, MVD, CASK, HSPA1A, LATS1, STK40
    GO:0030554         adenyl nucleotide binding                    35 (12.4)   0.0392542     ACTBL2, GRPEL1, ERBB4, MVD, CASK, HSPA1A, LATS1, STK40

[^1]: Contributed equally
